Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Candel Therapeutics
Biotech
Biopsies illuminate potential of Candel's prostate cancer drug
Five months after revealing results of a prostate cancer trial, Candel has shown more data from the study, bolstering the value of CAN-2409.
Kevin Dunleavy
May 22, 2025 6:57pm
Candel's cancer survival data light path ahead in subpopulation
Mar 27, 2025 9:48am
Candel burns bright as phase 3 cancer win sends stock up 200%
Dec 11, 2024 9:49am
Candel’s flame dims as layoffs hit 50% of the team
Nov 28, 2023 11:23am
Homology shakes up leadership—Chutes & Ladders
Sep 9, 2022 9:30am
Candel nets downsized $72M IPO to advance cancer-killing viruses
Jul 27, 2021 3:44pm
